DenmarkDenmark

TopoTarget licences blood cancer drug to Spectrum

04.02.2010

Copenhagen/Irvine – Danish TopoTarget A/S has granted Spectrum Pharmaceuticals Inc the rights to market its blood cancer blockbuster drug candidate, Belinostat, in North America, India and China. Under terms of the agreement, Spectrum will pay $30m upfront for the first-in-class HDAC inhibitor, which is currently being tested in a phase III registration trial in relapsed or refractory Peripheral T-Cell Lymphoma as a monotherapy, with the expectation that it will be registered next year. In addition, the deal includes potential milestone payments of up to $320 million, and one million shares of Spectrum common stock, based upon the successful achievement of development, regulatory and commercial milestones, as well as double-digit royalties on net sales of Belinostat. TopoTarget will use the funds for commercialisation of its drug in Europe, Japan and the rest of the world and expects worldwide peak sales of $64m in this indication. While there are only 66,000 new cases per year and no treatment available, Belinostat has been granted Orphan Drug status and fast track designation by the FDA. The HDAC inhibitor shows no significant bone toxicity and thus can be combined with full dose chemotherapy regimens. If also approved in Carcinoma Of Unknown Primary (CUP) peak sales of $1.2bn are anticipated Spectrum and TopoTarget will jointly fund development activities, whereby new clinical trial costs will be borne 70% by Spectrum and 30% by TopoTarget.

DenmarkDenmark

07.03.2012

Bagsvaerd/Bangalore – Danish Novozymes A/S has begun a new collaboration with Indian Sea6 Energy. The companies will jointly develop enzymes to convert seaweed-based carbohydrates to sugar, which can then be fermented to produce...

DenmarkDenmark

06.03.2012

Prague/Turku/Copenhagen – Danish pharmaceutical company H. Lundbeck A/S yesterday unveiled clinical data on its potential blockbuster drug nalmefene at the 2012 European Congress of Psychiatry clinical in Prague. While Lundbeck...

DenmarkDenmark

05.03.2012

Copenhagen – With the in vitro proof of concept for an undisclosed antibody target, Genmab A/S has reached the second milestone in its collaboration with H. Lundbeck A/S. Genmab will now receive a €1m payment. Under the...

DenmarkDenmark

01.02.2012

Copenhagen/Bangalore – Biofuels need reliable sources of biomass. Novozymes now looks to the ocean to secure biomass. The Danish enzyme specialist announced an exploratory research agreement with Sea6 Energy from India. The...

DenmarkDenmark

02.01.2012

Copenhagen – Hellsinn Healthcare has successfully completed a phase Ib trial in Europe with Zealand Pharma’s GLP-2 (glucagone-like peptide 2) peptide antagonist Elsiglutide (ZP1846). The completion of the study, which was...

DenmarkDenmark

23.12.2011

Copenhagen - An alliance of giants will take a thorough look into biofuels for the maritime sector. The leading enzyme producer Novozymes will team up with parts of the Danish shipping industry, including the world’s largest...

DenmarkDenmark

17.12.2011

Copenhagen/Paris – Danish biopharma­ceuticals company Zealand Pharma A/S has received some positive news. Ever since French partner Sanofi Aventis submitted a marketing authorisation application for Lyxumia (lixisenatide) in...

DenmarkDenmark

07.11.2011

Copenhagen/Paris - The cooperation between Danish biopharmaceutical company Zealand Pharma and French drugmaker Sanofi has borne its first fruit. Sanofi has submitted a marketing authorisation application for Lyxumia...

DenmarkDenmark

01.10.2011

Copenhagen/Ingelheim – Danish HTS expert Nuevolution A/S has signed a license agreement with drugmaker Boeh­ringer Ingelheim (BI). The German pharma company will use Nuevolution’s proprietary Chemetics drug discovery technology...

DenmarkDenmark

25.08.2011

Bagsværd - Novo Nordisk is investing around €134m in a new corporate centre in the Copenhagen suburb Bagsværd. The new office premises will concentrate the top management and 1,100 administrative employees which are currently...

Displaying results 1 to 10 out of 194

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-denmark/article/topotarget-licences-blood-cancer-drug-to-spectrum.html

Events

All Events

Stock list

All quotes

TOP

  • WILEX2.40 EUR6.67%
  • SANTHERA100.10 CHF1.78%
  • ACTELION112.70 CHF1.35%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • VITA 343.70 EUR-5.85%
  • EVOTEC3.68 EUR-1.60%

TOP

  • SANTHERA100.10 CHF67.1%
  • BB BIOTECH142.65 EUR10.2%
  • MAGFORCE6.80 EUR6.1%

FLOP

  • MOLOGEN7.31 EUR-14.0%
  • THERAMETRICS0.07 CHF-12.5%
  • VITA 343.70 EUR-11.1%

TOP

  • SANTHERA100.10 CHF4388.8%
  • CO.DON2.51 EUR213.7%
  • PAION2.43 EUR173.0%

FLOP

  • CYTOS0.25 CHF-93.7%
  • MEDIGENE4.53 EUR-67.5%
  • THERAMETRICS0.07 CHF-53.3%

No liability assumed, Date: 31.08.2014


Current issue

All issues

Product of the week

Products